Bochum, 10th February 2021. Despite a challenging year 2020, Phenox GmbH is pursuing its strategic plans in strengthening the footprint in key markets across Europe. As part of this strategy and in the light of Brexit, Phenox has taken the decision to open a UK entity materialising in its new office south of Birmingham.
Phenox UK’s orders will now be processed through the UK entity with the creation of additional headcounts. Thus, Phenox continues to be committed to contributing to the local economies of the countries it provides services in. To date, Phenox has sites in Germany, Ireland, UK, USA and Italy (also a 2021 addition) using the resource of local employment in each country.
“This is a very exciting time for Phenox GmbH; going direct in Italy and the UK after a very challenging, yet successful 2020 operating in a pandemic that the world has never faced before. Phenox GmbH is going from strength to strength”- Prof. Dr.-Ing. Hermann Monstadt, Managing Partner.
Alongside adding headcounts in HQ UK, Phenox UK is adding more headcounts in sales to strengthen the sales team and achieve higher service levels for its UK and Ireland customers by improving coverage. Along with the addition of headcounts, Phenox GmbH is at the forefront of developing new devices with its in-house engineers, consolidating Phenox as market leaders in Neurointerventional Radiology.
“The neurovascular space is an exciting field to be involved in, new technologies are emerging constantly and Phenox GmbH are at the cutting-edge of that. Our breakthrough HPC-technology, which is gaining more and more attention worldwide is just one example of our innovative spirit. Coming from a strong series of years with many innovations brought to the market, 2021 will be no different.”- Ralf Hannes, Managing Partner
Since its founding in 2005, Phenox has been dedicated to developing innovative clinically proven breakthrough technologies and solutions for treating neurovascular diseases. Endovascular specialists use Phenox products to treat ischemic and hemorrhagic strokes.
Phenox offers an expanding portfolio of innovative treatment options, including primary interventional technologies used today. Its product range consists of the pRESET mechanical thrombectomy system, the p64, p64 MW and p48 MW Flow Diverters for treating complex intracranial aneurysms and dissections, and the pCONUS implant for treating complex, wide-neck bifurcation aneurysms. The proprietary HPC technology leads to increased patient safety by significantly reducing thrombogenicity of implant surfaces. In 2020, Phenox became the exclusive distributor for the Avenir Coiling System in the US and Europe.
Phenox’s main office is located in Bochum, Germany with subsidiaries located in Galway, Ireland, the UK, Italy, and Irvine, California (USA). Phenox is a private company, financed by private funds as well as the NRW BANK, Venture Fond GmbH & Co.KG, together with SHS Technologiefonds GmbH & Co.KG.
For more information about Phenox and its products, visit http://www.phenox.net/
Phenox and its products are registered trademarks of Phenox GmbH, registered in Germany and other countries. All other trademarks and trade names used in in this press release are the property of their respective owners.
Lise-Meitner-Allee 31 - 44801 Bochum, Germany
Tel.: +49 (0)234 36 919 0 - Fax: +49 (0)234 36 919 19
CEO: Dr.-Ing. Hermann Monstadt, Ralf Hannes
Registry Court: AG Bochum, HRB 10388